Prekyba Agios Pharmaceuticals, Inc. - AGIO CFD
Pridėti prie mėgstamų- Santrauka
- Istoriniai duomenys
- Įvykiai
- Pajamų ataskaita
- Balansas
- Pinigų srautai
- Nuosavybė
Skirtumas | 0.22 | ||||||||
Ilgos pozicijos nakties mokestis
Long position overnight fee
Eiti į platformą | -0.025457% | ||||||||
Trumpos pozicijos nakties mokestis
Short position overnight fee
Eiti į platformą | 0.003235% | ||||||||
Nakties mokesčio laikas | 21:00 (UTC) | ||||||||
Mažiausias parduodamas kiekis | 1 | ||||||||
Valiuta | USD | ||||||||
Marža | 20% | ||||||||
Akcijų birža | United States of America | ||||||||
Prekybos mokesčiai | 0% |
*Information provided by Capital.com
Agios Pharmaceuticals Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Ankstesnis uždarymas* | 25.55 |
Atviras* | 25.64 |
1 metų pokytis* | 34.24% |
Dienos intervalas* | 25.57 - 26.14 |
52 savaičių intervalas | 16.75-34.76 |
Vidutinė apimtis (10 dienų) | 393.15K |
Vidutinė apimtis (3 mėn.) | 10.10M |
Rinkos kapitalizacija | 1.45B |
P/E santykis | -100.00K |
Neišpirktos akcijos | 55.58M |
Pajamos | 19.02M |
EPS | -3.97 |
Dividendai (pajamingumas %) | N/A |
Beta | 0.94 |
Kito pelno data | Aug 2, 2023 |
Visus duomenis pateikė Refinitiv, išskyrus žvaigždute pažymėtus duomenis, kurie yra Capital.com pateikti *duomenys
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Uždarymas | Change | Change (%) | Atidarymas | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 25.94 | 1.14 | 4.60% | 24.80 | 26.25 | 24.80 |
Jun 1, 2023 | 25.55 | 0.61 | 2.45% | 24.94 | 25.83 | 24.43 |
May 31, 2023 | 25.22 | -0.08 | -0.32% | 25.30 | 26.31 | 25.03 |
May 30, 2023 | 25.16 | -0.63 | -2.44% | 25.79 | 26.18 | 24.91 |
May 26, 2023 | 25.74 | 0.82 | 3.29% | 24.92 | 25.91 | 24.92 |
May 25, 2023 | 25.68 | -0.21 | -0.81% | 25.89 | 26.05 | 25.15 |
May 24, 2023 | 26.67 | 0.80 | 3.09% | 25.87 | 27.02 | 25.87 |
May 23, 2023 | 26.96 | 0.68 | 2.59% | 26.28 | 27.77 | 25.85 |
May 22, 2023 | 26.52 | 0.55 | 2.12% | 25.97 | 26.81 | 25.65 |
May 19, 2023 | 25.92 | 0.44 | 1.73% | 25.48 | 26.21 | 25.34 |
May 18, 2023 | 25.76 | 0.95 | 3.83% | 24.81 | 25.87 | 24.81 |
May 17, 2023 | 25.88 | 1.19 | 4.82% | 24.69 | 25.99 | 24.69 |
May 16, 2023 | 25.37 | 0.09 | 0.36% | 25.28 | 25.58 | 24.96 |
May 15, 2023 | 26.06 | 0.92 | 3.66% | 25.14 | 26.65 | 25.11 |
May 12, 2023 | 25.27 | 0.05 | 0.20% | 25.22 | 25.42 | 24.55 |
May 11, 2023 | 25.22 | 0.27 | 1.08% | 24.95 | 25.60 | 24.30 |
May 10, 2023 | 25.42 | 0.27 | 1.07% | 25.15 | 25.93 | 25.10 |
May 9, 2023 | 25.23 | 0.80 | 3.27% | 24.43 | 25.57 | 24.30 |
May 8, 2023 | 25.28 | 0.24 | 0.96% | 25.04 | 25.65 | 24.88 |
May 5, 2023 | 25.32 | 1.15 | 4.76% | 24.17 | 26.61 | 24.17 |
Agios Pharmaceuticals, Inc. Events
Laikas (UTC) (UTC) | Šalis | Įvykis |
---|---|---|
Wednesday, June 21, 2023 | ||
Laikas (UTC) (UTC) 13:00 | Šalis US
| Įvykis Agios Pharmaceuticals Inc Annual Shareholders Meeting Agios Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
Wednesday, August 2, 2023 | ||
Laikas (UTC) (UTC) 12:30 | Šalis US
| Įvykis Q2 2023 Agios Pharmaceuticals Inc Earnings Release Q2 2023 Agios Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
Wednesday, November 1, 2023 | ||
Laikas (UTC) (UTC) 12:30 | Šalis US
| Įvykis Q3 2023 Agios Pharmaceuticals Inc Earnings Release Q3 2023 Agios Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Metinis
- Kas ketvirtį
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Visos pajamos | 14.24 | 0 | 0 | 0 | 94.387 |
Pajamos | 14.24 | 94.387 | |||
Pajamų sąnaudos, iš viso | 265.583 | 371.779 | 335.916 | 316.269 | 456.866 |
Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 121.673 | 121.445 | 115.105 | 102.007 | 114.145 |
Tyrimai ir plėtra | 279.91 | 256.973 | 220.811 | 214.262 | 341.324 |
Veiklos pajamos | -251.343 | -371.779 | -335.916 | -316.269 | -362.479 |
Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 12.793 | 0.836 | 6.611 | 14.861 | 16.451 |
Grynosios pajamos prieš mokesčius | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
Grynosios pajamos po mokesčių | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
Grynosios pajamos prieš papildomas. Prekės | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
Grynosios pajamos | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
Total Adjustments to Net Income | |||||
Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -231.801 | -356.51 | -329.305 | -301.408 | -346.028 |
Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
Skiedžiamas grynasis pelnas | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
Skiedžiamas svertinis vidutinis akcijų skaičius | 54.7894 | 60.4473 | 68.9979 | 59.9945 | 57.4183 |
Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -4.23076 | -5.89786 | -4.77268 | -5.02392 | -6.02644 |
Dividends per Share - Common Stock Primary Issue | |||||
Skiedžiamas normalizuotas pelnas, gautas iš pelno | -6.74409 | -6.00769 | -4.77268 | -5.02392 | -6.02644 |
Iš viso nepaprastųjų prekių | 0 | 1961.22 | 1.935 | -110.064 | |
Bendros pajamos, iš viso | 1.704 | 1.397 | |||
Pajamos | 12.536 | 92.99 | |||
Neįprastos išlaidos (pajamos) | -137.704 | -6.639 | 0 | 0 | |
Kita, pajamos | 6.749 | 14.433 | 0 | 0 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Visos pajamos | 5.609 | 4.31 | 3.516 | 5.582 | 0.832 |
Pajamų sąnaudos, iš viso | 96.222 | -24.371 | 90.163 | 100.518 | 99.273 |
Pardavimas / Bendrosios / administravimo išlaidos, iš viso | 28.367 | 32.771 | 29.123 | 28.264 | 31.515 |
Tyrimai ir plėtra | 67.301 | 70.298 | 64.966 | 74.523 | 70.123 |
Veiklos pajamos | -90.613 | 28.681 | -86.647 | -94.936 | -98.441 |
Palūkanų pajamos (išlaidos), grynosios ne veiklos pajamos | 8.091 | 6.488 | 3.818 | 1.793 | 0.694 |
Grynosios pajamos prieš mokesčius | -81.018 | 36.526 | -81.747 | -91.806 | -94.774 |
Grynosios pajamos po mokesčių | -81.018 | 36.526 | -81.747 | -91.806 | -94.774 |
Grynosios pajamos prieš papildomas. Prekės | -81.018 | 36.526 | -81.747 | -91.806 | -94.774 |
Iš viso nepaprastųjų prekių | 0 | 0 | 0 | 0 | |
Grynosios pajamos | -81.018 | 36.526 | -81.747 | -91.806 | -94.774 |
Pajamos, kurias galima gauti bendrai, išskyrus papildomas pajamas. Prekės | -81.018 | 36.526 | -81.747 | -91.806 | -94.774 |
Pajamos, kurias galima gauti bendrai, įskaitant papildomas pajamas. Prekės | -81.018 | 36.526 | -81.747 | -91.806 | -94.774 |
Skiedžiamas grynasis pelnas | -81.018 | 36.526 | -81.747 | -91.806 | -94.774 |
Skiedžiamas svertinis vidutinis akcijų skaičius | 55.2654 | 54.9548 | 54.8446 | 54.7997 | 54.5555 |
Skiedžiamas pelnas už akcijas, neįskaitant ypatingų prekių | -1.46598 | 0.66465 | -1.49052 | -1.6753 | -1.7372 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Skiedžiamas normalizuotas pelnas, gautas iš pelno | -1.46598 | -1.66186 | -1.57153 | -1.72465 | -1.78677 |
Neįprastos išlaidos (pajamos) | 0 | -127.853 | -4.443 | -2.704 | -2.704 |
Kita, pajamos | 1.504 | 1.357 | 1.082 | 1.337 | 2.973 |
Pajamos | 5.609 | 4.31 | 3.516 | 5.582 | 0.832 |
Bendros pajamos, iš viso | 0.554 | 0.413 | 0.517 | 0.435 | 0.339 |
Pajamos | 5.055 | 3.897 | 2.999 | 5.147 | 0.493 |
- Metinis
- Kas ketvirtį
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Trumpalaikis turtas iš viso | 832.772 | 1064.23 | 636.677 | 611.704 | 613.78 |
Pinigai ir trumpalaikės investicijos | 783.119 | 1020.02 | 572.929 | 564.877 | 585.302 |
Pinigai ir ekvivalentai | 139.259 | 203.126 | 127.436 | 80.931 | 70.502 |
Trumpalaikės investicijos | 643.86 | 816.892 | 445.493 | 483.946 | 514.8 |
Gautinos sumos, iš viso, grynąja verte | 2.206 | 4.378 | 25.399 | 15.319 | 10.442 |
Prepaid Expenses | 38.955 | 39.835 | 23.651 | 24.177 | 17.167 |
Total Assets | 1238.72 | 1437.74 | 852.952 | 890.741 | 858.457 |
Property/Plant/Equipment, Total - Net | 88.116 | 104.23 | 117.542 | 126.108 | 24.32 |
Property/Plant/Equipment, Total - Gross | 138.186 | 149.204 | 158.895 | 158.22 | 50.472 |
Accumulated Depreciation, Total | -50.07 | -44.974 | -41.353 | -32.112 | -26.152 |
Long Term Investments | 313.874 | 266.375 | 97.608 | 152.929 | 220.119 |
Other Long Term Assets, Total | 3.956 | 2.9 | 1.125 | 0 | 0.238 |
Total Current Liabilities | 62.629 | 59.826 | 94.394 | 92.886 | 93.503 |
Accounts Payable | 18.616 | 16.7 | 26.844 | 21.896 | 17.88 |
Accrued Expenses | 44.013 | 42.795 | 67.233 | 59.784 | 42.147 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 0 | 0 | 10.933 | 33.476 | |
Total Liabilities | 137.904 | 145.761 | 453.452 | 250.213 | 170.92 |
Total Long Term Debt | 0 | 0.276 | 0.331 | 0.673 | 0 |
Other Liabilities, Total | 75.275 | 85.659 | 358.727 | 156.654 | 77.417 |
Total Equity | 1100.81 | 1291.97 | 399.5 | 640.528 | 687.537 |
Common Stock | 0.071 | 0.071 | 0.069 | 0.068 | 0.058 |
Additional Paid-In Capital | 2386.32 | 2334.35 | 2242.8 | 2156.36 | 1794.28 |
Retained Earnings (Accumulated Deficit) | -470.561 | -238.76 | -1843.47 | -1516.1 | -1104.63 |
Other Equity, Total | -12.535 | -1.198 | 0.105 | 0.202 | -2.171 |
Total Liabilities & Shareholders’ Equity | 1238.72 | 1437.74 | 852.952 | 890.741 | 858.457 |
Total Common Shares Outstanding | 55.0397 | 54.3342 | 69.2939 | 68.4011 | 58.2187 |
Accounts Receivable - Trade, Net | 2.206 | 21.328 | 11.852 | 7.31 | |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Total Inventory | 8.492 | 14.698 | 7.331 | 0.869 | |
Current Port. of LT Debt/Capital Leases | 0 | 0.331 | 0.317 | 0.273 | |
Capital Lease Obligations | 0 | 0.276 | 0.331 | 0.673 | |
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | |
Other Current Assets, Total | 0 | ||||
Treasury Stock - Common | -802.486 | -802.486 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Trumpalaikis turtas iš viso | 791.656 | 832.772 | 784.935 | 870.007 | 975.145 |
Pinigai ir trumpalaikės investicijos | 739.201 | 783.119 | 727.68 | 819.309 | 923.529 |
Pinigai ir ekvivalentai | 104.139 | 139.259 | 122.449 | 88.543 | 80.026 |
Trumpalaikės investicijos | 635.062 | 643.86 | 605.231 | 730.766 | 843.503 |
Prepaid Expenses | 39.303 | 38.955 | 46.487 | 42.336 | 43.226 |
Other Current Assets, Total | |||||
Total Assets | 1151.3 | 1238.72 | 1180.32 | 1252.47 | 1335.86 |
Property/Plant/Equipment, Total - Net | 83.959 | 88.116 | 93.13 | 97.66 | 101.978 |
Long Term Investments | 271.727 | 313.874 | 298.352 | 280.845 | 255.836 |
Other Long Term Assets, Total | 3.956 | 3.956 | 3.903 | 3.955 | 2.9 |
Total Current Liabilities | 45.113 | 62.629 | 53.596 | 48.396 | 45.792 |
Accounts Payable | 8.662 | 18.616 | 10.415 | 7.79 | 11.551 |
Accrued Expenses | 36.451 | 44.013 | 43.098 | 40.439 | 31.491 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0.083 | 0.167 | 0.25 | |
Other Current Liabilities, Total | 2.5 | ||||
Total Liabilities | 114.772 | 137.904 | 130.15 | 128.397 | 128.406 |
Total Long Term Debt | 0 | 0 | 1.055 | 1.055 | 0.276 |
Capital Lease Obligations | 0 | 1.055 | 1.055 | 0.276 | |
Other Liabilities, Total | 69.659 | 75.275 | 75.499 | 78.946 | 82.338 |
Total Equity | 1036.53 | 1100.81 | 1050.17 | 1124.07 | 1207.45 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
Common Stock | 0.072 | 0.071 | 0.071 | 0.071 | 0.071 |
Additional Paid-In Capital | 2398.93 | 2386.32 | 2374.75 | 2362.33 | 2351.15 |
Retained Earnings (Accumulated Deficit) | -551.579 | -470.561 | -507.087 | -425.34 | -333.534 |
Other Equity, Total | -8.411 | -12.535 | -15.083 | -10.502 | -7.745 |
Total Liabilities & Shareholders’ Equity | 1151.3 | 1238.72 | 1180.32 | 1252.47 | 1335.86 |
Total Common Shares Outstanding | 55.5414 | 55.0397 | 54.894 | 54.8154 | 54.7769 |
Total Preferred Shares Outstanding | 0 | 0 | 0 | 0 | 0 |
Gautinos sumos, iš viso, grynąja verte | 1.778 | 2.206 | 5.592 | 4.302 | 5.905 |
Treasury Stock - Common | -802.486 | -802.486 | -802.486 | -802.486 | -802.486 |
Accounts Receivable - Trade, Net | 1.778 | 2.206 | 1.818 | 1.598 | 0.54 |
Total Inventory | 11.374 | 8.492 | 5.176 | 4.06 | 2.485 |
- Metinis
- Kas ketvirtį
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Grynosios pajamos / pradinė eilutė | -231.801 | 1604.71 | -327.37 | -411.472 | -346.028 |
Pagrindinės veiklos pinigai | -309.478 | -407.32 | -290.759 | -370.622 | -304.421 |
Pagrindinės veiklos pinigai | 8.564 | 9.24 | 9.984 | 8.087 | 7.172 |
Nepiniginės prekės | -69.808 | -1984.45 | 97.664 | 78.762 | 69.54 |
Cash Taxes Paid | |||||
Apyvartinio kapitalo pokyčiai | -16.433 | -36.822 | -71.037 | -45.999 | -35.105 |
Investicinės veiklos pinigai | 243.261 | 1248.78 | 75.746 | 91.44 | -273.825 |
Kapitalo išlaidos | -4.881 | -5.741 | -14.909 | -12.171 | -6.986 |
Kiti investiciniai pinigų srautų iš prekių, iš viso | 248.142 | 1254.52 | 90.655 | 103.611 | -266.839 |
Finansinės veiklos pinigai | 2.35 | -765.768 | 261.518 | 289.611 | 546.024 |
Finansavimo pinigų srautų prekės | 0 | 0 | 250.537 | 0 | -0.391 |
Akcijų išleidimas (išpirkimas), grynasis | 2.681 | -765.19 | 11.317 | 289.724 | 546.415 |
Grynasis pinigų pokytis | -63.867 | 75.69 | 46.505 | 10.429 | -32.222 |
Skolos išleidimas (padengimas), grynasis | -0.331 | -0.578 | -0.336 | -0.113 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -81.018 | -231.801 | -268.327 | -186.58 | -94.774 |
Cash From Operating Activities | -95.183 | -309.478 | -243.315 | -171.964 | -97.735 |
Cash From Operating Activities | 1.79 | 8.564 | 6.75 | 4.769 | 2.478 |
Non-Cash Items | 9.821 | -69.808 | 46.013 | 32.986 | 19.096 |
Changes in Working Capital | -25.776 | -16.433 | -27.751 | -23.139 | -24.535 |
Cash From Investing Activities | 57.596 | 243.261 | 160.31 | 56.24 | -26.573 |
Capital Expenditures | -0.399 | -4.881 | -4.768 | -4.73 | -2.804 |
Other Investing Cash Flow Items, Total | 57.995 | 248.142 | 165.078 | 60.97 | -23.769 |
Cash From Financing Activities | 2.467 | 2.35 | 2.328 | 1.141 | 1.208 |
Issuance (Retirement) of Stock, Net | 2.467 | 2.681 | 2.576 | 1.305 | 1.289 |
Issuance (Retirement) of Debt, Net | 0 | -0.331 | -0.248 | -0.164 | -0.081 |
Net Change in Cash | -35.12 | -63.867 | -80.677 | -114.583 | -123.1 |
Financing Cash Flow Items | 0 | 0 | 0 | 0 |
Investuotojo pavadinimas | Investuotojo tipas | Apyvartoje esantis procentas | Turimos akcijos | Turimų akcijų pokytis | Turėjimo data | Apyvartos vertinimas |
---|---|---|---|---|---|---|
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 10.297 | 5723131 | 260474 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 9.7336 | 5410000 | 86563 | 2023-03-31 | LOW |
Bellevue Asset Management AG | Investment Advisor | 7.221 | 4013500 | -43292 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 7.0914 | 3941484 | 24043 | 2023-03-31 | LOW |
Armistice Capital LLC | Hedge Fund | 6.2252 | 3460000 | 710000 | 2023-03-31 | HIGH |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.5127 | 3064002 | -115066 | 2023-03-31 | LOW |
Rock Springs Capital Management LP | Hedge Fund | 4.7887 | 2661605 | -334987 | 2023-03-31 | LOW |
Farallon Capital Management, L.L.C. | Hedge Fund | 3.7654 | 2092829 | 67000 | 2023-03-31 | MED |
Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 3.7627 | 2091351 | 438272 | 2023-03-31 | LOW |
First Trust Advisors L.P. | Investment Advisor | 3.3062 | 1837617 | 206791 | 2023-03-31 | LOW |
ArrowMark Colorado Holdings, LLC | Investment Advisor/Hedge Fund | 2.8026 | 1557705 | 116719 | 2023-03-31 | LOW |
Macquarie Investment Management | Investment Advisor | 2.6041 | 1447388 | 34979 | 2023-03-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 2.1334 | 1185745 | -211429 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.96 | 1089359 | 33801 | 2023-03-31 | LOW |
BNP Paribas Asset Management USA, Inc. | Investment Advisor | 1.847 | 1026587 | 10708 | 2023-03-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 1.7403 | 967251 | -11862 | 2023-03-31 | MED |
JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.7219 | 957028 | 0 | 2023-03-31 | LOW |
Fisher Investments | Investment Advisor/Hedge Fund | 1.5316 | 851288 | -25665 | 2023-03-31 | LOW |
Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.3614 | 756684 | -664652 | 2023-03-31 | LOW |
Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.2524 | 696076 | 430358 | 2023-03-31 | LOW |
Kodėl Capital.com? Mūsų skaičiai kalba už save.
Capital.com Group535K+
Prekeiviai
87K+
Aktyvūs klientai kas mėnesį
$113M+
Mėnesio investicijų apimtis
$64M+
Atsiimama kas mėnesį
Prekybos skaičiuoklė
Apskaičiuokite savo hipotetinį pelną ir pelną, jei CFD sandorį atidarėte tam tikrą dieną (pasirinkite datą) ir uždarėte kitą dieną (pasirinkite datą).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Agios Pharmaceuticals, Inc. Company profile
Apie Agios Pharmaceuticals, Inc.
"Agios Pharmaceuticals, Inc." yra biofarmacijos bendrovė. Pagrindinis bendrovės genetiškai apibrėžtų ligų (GDD) portfelio produktas PYRUKYND (Mitapivat) yra laukinio tipo ir įvairių mutavusių piruvato kinazės (PK) fermentų aktyvatorius, skirtas hemolizinėms anemijoms gydyti. Mitapivat yra per burną vartojama maža molekulė ir stiprus piruvato kinazės R (PKR) fermentų aktyvatorius. Be to, šiuo metu atliekamuose klinikiniuose tyrimuose "Mitapivat" taip pat vertinamas a- ir b-talasemijai bei pjautuvo pavidalo ląstelių ligai (SCD) gydyti. Bendrovė taip pat kuria AG-946 - klinikinės stadijos geriamąjį PKR fermentų aktyvatorių, skirtą hemolizinėms anemijoms ir kitoms indikacijoms, įskaitant SCD ir anemiją, susijusią su mažos ar vidutinės rizikos mielodisplaziniu sindromu (L-IR MDS), gydyti; šiuo metu atliekamas I fazės klinikinis tyrimas.
Industry: | Bio Therapeutic Drugs |
88 Sidney Street
CAMBRIDGE
MASSACHUSETTS 02139
US
Pajamų ataskaita
- Annual
- Quarterly
Žmonės taip pat žiūri
Vis dar ieškote brokerio kuriuo galėtumėte pasitikėti?
Prisijunkite prie 535 000+ prekeivių visame pasaulyje, kurie pasirinko prekybą su Capital.com